US Patent

US11058677 — LFA-1 inhibitor formulations

Formulation · Assigned to Novartis AG · Expires 2033-12-18 · 8y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects formulations for treating dry eye diseases, including a stabilized pharmaceutical composition of the compound of Formula 1.

USPTO Abstract

The present invention provides formulations, methods and kits for the treatment of dry eye diseases. In particular, stabilized pharmaceutical compositions comprising the compound of Formula 1 are described herein for a variety of uses including the treatment of dry eye syndrome. In one aspect, methods and ingredients for improving the stability of compositions of the compound of Formula 1 are described.

Drugs covered by this patent

Patent Metadata

Patent number
US11058677
Jurisdiction
US
Classification
Formulation
Expires
2033-12-18
Drug substance claim
No
Drug product claim
Yes
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.